[Funding alert] Switzerland-based Medical Device Company Aesyra Secures $3m in Seed Funding

Read also - Swiss Startup PLAN-B NET ZERO Secures €9.2 Million in Series A Round Funding

The new financing will support the development and commercialization of Aesyra’s AesyBite™ line of products for accurate monitoring and treatment of sleep bruxism and sleep apnea.

Marco Letizia, founder and CEO of Aesyra said, “This significant investment marks a pivotal moment for Aesyra, We are thrilled to partner with Supermoon Capital and Creadd Ventures, who share our vision of driving meaningful change within the sleep industry. With their support, we are well-positioned to accelerate the deployment of our groundbreaking solutions, ultimately improving patient outcomes and advancing healthcare practices.”

Michael Masterson, Managing Partner at Supermoon Capital said, “Aesyra’s advanced technology is a tremendous breakthrough in the field of sleep science for the treatment of sleep bruxism and sleep apnea, We are impressed by the company’s unique approach, strong leadership team and unwavering commitment to revolutionize healthcare, and we are looking forward to working closely with Aesyra to support its mission.”

Lorenzo Leoni, Founder and Managing Partner at Creadd Ventures said, “We selected Aesyra as the first investment of Creadd Ventures since it perfectly fits our philosophy to invest in companies that have the potential to make a profound impact on the quality of life of patients,”.

About Aesyra

In November 2017, Aesyra SA was founded as a spin-off of EPFL, closely collaborating with medical specialists from the Clinique Universitaire de Médecine Dentaire de Genève (CUMD).

Read also - Belgian Sports Tech Startup Raw Stadia Secures €1.5 Million in Funding

The objective of Aesyra is to develop, manufacture, and market a medical device that can precisely track a patient's jaw motions as they sleep and offer active biofeedback to lessen teeth grinding without waking the patient up.